Welcome to kongre.net

RT

SummitIn personPast event

8th RAS-Targeted Drug Development Summit

Hosted by Hanson Wade

8 – 10 September 2026
The Colonnade Hotel, Boston, United States of America
Health SciencesPharmacy & Pharmaceutical Sciences

Let others know you'll be there. This does not register you for the event.

Welcome to kongre.net

Welcome to kongre.net

Official website

Programme

Published

37 sessions across 3 days

33 speakers

Browse programme

Registration

Event has ended

Registration is handled by the organiser

Fees are listed on this page

View registration details

Key facts

8th RAS-Targeted Drug Development Summit is a summit held 8 – 10 September 2026 in The Colonnade Hotel, Boston, United States of America, organised by Hanson Wade.

Dates:: 8 – 10 September 2026
Format:: In person
Venue:: The Colonnade Hotel, Boston, United States of America
Subjects:: Pharmacy & Pharmaceutical Sciences
Organiser:: Hanson Wade
Official website:: ras-drugdevelopment.com

The 8th RAS-Targeted Drug Development Summit is an industry-focused forum dedicated exclusively to translating RAS-targeted therapies from early discovery through clinical development. Organized by Hanson Wade, the event takes place in Boston, MA from September 8 to 10, 2026. It gathers biopharma and academic leaders to discuss next-generation inhibitors, pan-RAS strategies, novel modalities, overcoming resistance, and designing smarter combination regimens across RAS-driven tumors.

Programme highlights

View full programme

Tue, 8 Sept 2026Chair’s Opening RemarksPlenary11 sessions this day
Wed, 9 Sept 2026Chair’s Opening RemarksPlenary14 sessions this day
Thu, 10 Sept 2026Chair’s Opening RemarksPlenary12 sessions this day

Speakers

View all 33 speakers

Michael Hamilton
Vividion Therapeutics
Disruption of the RAS-PI3Kα Interaction Provides Enhanced Efficacy in Combination Mutant KRAS Targeting Therapies
Myles Walsh
Predicine
Advancing RAS-Targeted Drug Development with Ultra-Deep Genomics, Personalized MRD, and Multi-Omic Resistance Monitoring
Mitchell Shirvan
Silexion Therapeutics
SIL204, an Isoform-Selective Pan-KRAS Silencing Stable siRNA with Dual-Delivery Administration for Pancreatic Cancer: Phase 2 Early Safety Findings & Supporting Preclinical Data
Michael Sweeney
Biodesix
Beyond Tissue: Liquid Biopsy Quantification of RAS Mutations and Proteomic Profiling for Patient Selection and Longitudinal Trial Monitoring
Jeffery Kutok
Ensem Therapeutics
ETX-929, A Potential Best-In-Class, Oral, Highly Potent & Selective Dual ON / OFF State Pan-KRAS Small Molecule Inhibitor for the Treatment of KRAS Mutant & Wild-type Amplified Cancers
Ivana Sullivan
Amgen Inc.
Advancing First Line Care for KRAS G12C positive & PD L1 negative NSCLC: Optimizing Targeted Therapy + Chemotherapy for a High-Unmet- Need Population
Nagi Ayad
Georgetown University
Expanding the Druggable Landscape: Targeting Signalling, Cytoskeletal & Chromatin Pathways to Unlock Next-Generation RAS Combination Strategies
Andreas Varkaris
Harvard Medical School
Is Perfect Selectivity Necessary? Rethinking KRAS Targeting in the Era of Resistance

Venue & travel The Colonnade HotelBoston, United States of AmericaVenue details About the organiser Hanson Wade4 more events from this organiserOrganiser profile Who is going? See who attended this eventSee who is going

Organiser and contact

Host organisation

Hanson Wade 4 more events from Hanson Wade

Contact

Event secretary:: Anna Westgate-Maher
Email:: [email protected]

Advertisement

Related events